Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-02-28
2008-10-07
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S327100
Reexamination Certificate
active
07432295
ABSTRACT:
Novel18F-fluorine compounds useful for non-invasive imaging techniques such as PET, for detecting tissue hypoxia and methods for preparing them are disclosed. Novel intermediate compounds and methods for preparing them are also disclosed. Diagnostic kits useful in practicing the methods of claimed invention are also provided.
REFERENCES:
patent: 3505349 (1970-04-01), Beaman et al.
patent: 5540908 (1996-07-01), Koch et al.
patent: 5721265 (1998-02-01), Tracy et al.
patent: 5843404 (1998-12-01), Koch et al.
patent: 6252087 (2001-06-01), Koch et al.
patent: 6855828 (2005-02-01), Koch et al.
patent: 7230115 (2007-06-01), Dolbier et al.
patent: WO 01/07474 (2001-02-01), None
Adams, G.E., “Hypoxia-mediated drugs for radiation and chemotherapy,” Am.Cancer Soc., 1981, 48, 696-707.
Castelhano, et al., “Synthesis of α-amino acids with β, γ-unsaturated side chains,”Tetrahedron, 1988, 44(17), 5451-5466.
Castelhano, et al., “Reactions of an electrophilic glycine cation equivalent with Grignard reagents. A simple synthesis of β, γ-unsaturated amino acids,”Tetrahedron Letters, 1986, 27(22), 2435-2438.
Chapman, et al., “The fraction of hypoxic clonogenic cells in tumor populations,”Biological Bases and Clinical Implications of Tumor Radioresistance, 1983, Fletcher, G.H., et al. (Eds.), 61-73.
Chapman, J.D., et al., “Keynote address: Cellular reduction of nitroimidazole drugs: potential for selective chemotherapy and diagnosis of hypoxic cells,”Int. J. Radiat. Oncol. Biol. Phys., 1989, 16, 911-917.
Evans, S.M., et al., “Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1,”Journal of Nuclear Medicine, 2000, 41, 327-336.
Franko, A.J., et al., “Oxygen dependence of binding of misonidazole to rodent and human tumors in vitro,”Cancer Res., Oct. 15, 1987, 47, 5367-5376.
Grierson, J.R., et al., “A radiosynthesis of fluorine-18 fluoromisonidazole,”Journal of Nuclear Medicine, 1989, 30(3), 343-350.
Ido, T., et al., “Fluorination with F2-A convenient synthesis of 2-deoxy-2-fluoro-D-glucose,”J. Org. Chem., 1977, 42(13), 2341-2342.
Jerabek, P.A., et al., “Synthesis and biodistribution of18F-labeled fluoronitroimidazoles: potential in vivo markers of hypoxic tissue,”Applied Radiation&Isotopes, 1986, 37(7), 599-605.
Kennedy, K.A., et al., “The hypoxic tumor cell: a target for selective cancer chemotherapy,”Biochem. Pharm., 1980, 29, 1-8.
Koch, C.J., et al., “Metabolism induced binding of14C-Misonidazole to hypoxic cells: kinetic dependence of oxygen concentration and misonidazole concentration,”Int. J. Radiation Oncology Biol. Phys., 1984, 10, 1327-1331.
Koch, C.J., “The reduction activation of nitroimidazoles; modification by oxygen and other redox-active molecules in cellular systems,”Selective Activation of Drugs by Redox Processes, Plenum Press, NY, Adams, et al. (Eds.), 1990, 237-247.
Koch, C.J., “The mechanisms of radiation protection by non-protein sulfhydryls: glutathione, cysteine, and cysteamine,”CRC Press, 1998, 25-52.
Kachur, A.V., et al., “Synthesis of new hypoxia markers EF1 and [18F]-EF1,”Applied Radiation and Isotopes, 1999, 51(6), 643-650.
Koh, W.-J., et al., “imaging of hypoxia in human tumors with [F-18]fluoromisonidazole,”International Journal of Radiation Oncology Physics, 1992, 22(1), 199-212.
Koh, W.J., et al., “Positron emission tomography,”Acta Oncologica, 1994, 33(3), 323-327.
Mathias, et al., “Radiolabelled hypoxic cell sensitizers: tracers for assessment of ischemia,”Life Sciences, 1987, 41(2), 199-206.
Moulder, J.E., et al., “Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data,”Int. J. Radiat. Oncol. Biol. Phys., 1984, 10, 695-712.
Olah, G.A., et al., “Iodination of deactivated aromatics with N-iodosuccinimide in trifluoromethanesulfonic acid (NIS-CF3SO3H) via in situ generated superelectrophilic iodine(I) trifluoromethanesulfonate,”Synthesis, 1973, 4, 780-781.
Parlament, M.B., et al., “None-invasive assessment of human tumour hypoxia with123I-idoazomycin arabinoside: preliminary report of clinical study,”Br. J. Cancer, 1992, 65, 90-95.
Rasey, J.S., et al., “Characterization of radiolabeled fluorimisonidazole as a probe for hypoxic cells,”Radiat. Res., 1987, 111, 292-304.
Rasey, J.S., et al., “Characterization of [18F] fluroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia,”Journal of Nuclear Medicine, 1999, 40(6), 1072-1079.
Raleigh, J.A., et al., “Reductive fragmentation of 2-nitroimidazoles: amines and aldehydes,”Int. J. Radiat. Oncol. Biol. Phys., 1984, 10, 1337-1340.
Raleigh, J.A., et al., “Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours,”Br. J. Cancer, 1987, 56, 395-400.
Taylor, Y.C., et al., “Differences in the toxicity and metabolism of the 2-nitroimidazole misonidazole (R0-07-0582) in HeLa and Chinese hamster ovary cells,”Cancer Res., 1978, 38, 2745-2752.
Tewson, T.J., “Synthesis of [18F]fluoroetanidazole: a potential new tracer for imaging hypoxia,”Nuclear Medicine&Biology, 1997, 24, 755-760.
Valk, P.E., et al., “Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole,”Journal of Nuclear Medicine, 1992, 33(12), 2133-2137.
Varghese, A.J., et al., “Binding to cellular macromolecules as a possible mechanism for the cytotoxicity of misonidazole,”Cancer Res., 1980, 40, 2165-2169.
Williams, et al., “General synthesis of β-γ, alkynylglycine derivatives,”Journal of Organic Chemistry, 1990, 55(15), 4657-4663.
Yang, D.J., et al., “Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia,”Radiology, Mar. 1995, 194, 795-800.
Yeh, S.-H., et al., “Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma,”European Journal of Nuclear Medicine, 1996, 23(10), 1378-1383.
Waleh, N.S., et al., “Mapping of the vascular endothelial growth factor-producing hypoxic cells in multicellular tumor spheroids using a hypoxia-specific marker,”Cancer Research, 1995, 55, 6222-6226.
Rasey, J.S. et al., “Quantifying regional hypoxia in human tumors with positron emission tomography of [18F] fluoromisonidazole: a pretherapy study of 37 patients,”Int'l. J. of Rad. Onc. Bio. Phys., 1996, 36(2), 417-428.
Dolbier William R
Kachur Alexander V
Koch Cameron J
Li An-Rong
Saeed Kamal A
The Trustees Of The University of Pennsylvania
Woodcock & Washburn LLP
LandOfFree
Preparation of compounds useful for the detection of hypoxia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preparation of compounds useful for the detection of hypoxia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preparation of compounds useful for the detection of hypoxia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4006556